Allogeneic Stem Cell Transplantation for Children and Adolescents With Acute Lymphoblastic Leukaemia (NCT01949129)
🩺 Plain-English Summary (8th-Grade Level)
The ALL SCTped 2012 FORUM is a multinational, multi-centre, controlled, prospective phase III study for the therapy and therapy optimisation for children and adolescents with ALL in complete morphological remission (CR, less than 5% bone marrow blasts, no blasts in cerebrospinal fluid, no other extramedullary leukemia), who have an indication for HSCT with a myeloablative conditioning regimen. The stratification of patients in first and following remissions according to the individual transplantation modalities rests upon an indication for allogeneic HSCT and the availability of a suitable donor within the individual transplantation groups.
Who can join: Review the eligibility criteria below.
Location: Hospital de Pediatria "Juan P. Garrahan" Combate de Los Pozos N°1800 CABA — Buenos Aires
Age range: 1 Month to 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (119 Sites)
Showing the first 25 of 119 sites.
- Hospital de Pediatria "Juan P. Garrahan" Combate de Los Pozos N°1800 CABA — Buenos Aires,
- Hospital Sor Maria Ludovica, Department Hematology Stem Cell Transplant Unit — La Plata,
- Children's Cancer Centre The Royal Children's Hospital — Melbourne,
- Princess Margaret Hospital for Children — Perth,
- Sydney Children's Hospital — Randwick,
- Lady Cilento Children's Hospital — South Brisbane,
- The Children's Hospital at Westmead Oncology Unit — Sydney,
- Universitätsklinik für Kinder- und Jugendheilkunde, Abt. f. Hämato-Onkologie — Graz,
- Universitätsklinik für Kinder- und Jugendheilkunde — Innsbruck,
- St. Anna Children's Hospital, Vienna, Austria — Vienna,
- Belarusian Research Center for Pediatric Oncology, Hematology and Immunology — Minsk,
- Hôpital Universitaire des Enfants Reine Fabiola (HUDERF) — Brussels,
- Cliniques Universitaires Saint-Luc (UCL) Hématologie et oncologie pédiatrique — Brussels,
- University Hospital Gent Pediatrische hemato-oncologie — Ghent,
- University Hospitals Leuven Kinderhemato-oncologie — Leuven,
- Centre Hospitalier Universitaire de Liège Domaine Universitaire du Sart Tilman — Liège,
- Alberta Children's Hospital Division of Pediatric Oncology — Calgary,
- Montreal Children's Hospital — Montral,
- CHU Sainte-Justine Hematology-Oncology Division — Montreal,
- Hospital for Sick Children University of Toronto Division of Haematology/Oncology — Toronto,
- BC Children's Hospital — Vancouver,
- CancerCare Manitoba/University of Manitoba — Winnipeg,
- Hospital Dr Luis Calvo Mackenna — Santiago,
- Department of Pediatrics, UHC Zagreb — Zagreb,
- Department of Pediatric Hematology and Oncology Teaching Hospital Motol, 2nd Medical School, Charles University — Prague,
📞 Contact the Study Coordinator
Phone: +43140170
Email: christina.peters@stanna.at
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Acute Lymphoblastic Leukaemia
Explore by condition: All Acute Lymphoblastic Leukaemia clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.